297 related articles for article (PubMed ID: 27654028)
1. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
[TBL] [Abstract][Full Text] [Related]
2. Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases.
Schumacher-Kuckelkorn R; Hero B; Ernestus K; Berthold F
Pediatr Blood Cancer; 2005 Aug; 45(2):195-201. PubMed ID: 15800908
[TBL] [Abstract][Full Text] [Related]
3. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
4. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
5. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
6. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
7. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
8. [The morphological assessment of bone marrow infiltration in neuroblastoma].
Brisigotti M; Medicina D; Bercich L; Bonetti MF; Fabbretti G; Gambini C; Lo Piccolo MS; Milanaccio C; Rosanda C; Garaventa A; De Bernardi B; Callea F
Pediatr Med Chir; 1998; 20(3):169-74. PubMed ID: 9744007
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
10. Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma.
Cheung IY; Feng Y; Cheung NK
Pediatr Blood Cancer; 2013 Jul; 60(7):E32-4. PubMed ID: 23335404
[TBL] [Abstract][Full Text] [Related]
11. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
12. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
13. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
[TBL] [Abstract][Full Text] [Related]
14. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
[TBL] [Abstract][Full Text] [Related]
15. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
16. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
17. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.
Cheung IY; Barber D; Cheung NK
Clin Cancer Res; 1998 Nov; 4(11):2801-5. PubMed ID: 9829745
[TBL] [Abstract][Full Text] [Related]
18. Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.
Corrias MV; Parodi S; Haupt R; Lacitignola L; Negri F; Sementa AR; Dau D; Scuderi F; Carlini B; Bianchi M; Casale F; Faulkner L; Garaventa A
Br J Cancer; 2008 Jan; 98(2):263-9. PubMed ID: 18182983
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of autologous hematopoietic stem cell transplantation in the treatment of high-risk neuroblastoma in children: a single-center clinical study].
Wang LH; Chen K; Zhang N; Yang JW; Zhang T; Shao JB
Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):476-482. PubMed ID: 37272173
[TBL] [Abstract][Full Text] [Related]
20. Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow.
Manenq C; Lesesve JF; Dreumont N; Massin F; Salignac S; Mansuy L; Chastagner P; Latger-Cannard V; Broséus J
Int J Lab Hematol; 2020 Feb; 42(1):52-60. PubMed ID: 31821742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
